Answers are grounded in this paper and cite their sources.
A small molecule nonpeptide inhibitor of beta-secretase has been developed, and its binding has been defined through crystallographic determination of the enzyme-inhibitor complex. The molecule is shown to bind to the catalytic aspartate residues in an unprecedented manner in the field of aspartyl protease inhibition. Additionally, the complex reveals a heretofore unknown S(3) subpocket that is created by the inhibitor. This structure has served an important role in the design of newer beta-secretase inhibitors.
No takes yet. Share an insight, caveat, or question.
Coburn et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: